Tonix Pharmaceuticals (TNXP) Expected to Announce Quarterly Earnings on Monday

Tonix Pharmaceuticals (NASDAQ:TNXP) will likely be issuing its quarterly earnings data before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($6.23) per share and revenue of $3.35 million for the quarter.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($9.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.23) by ($3.54). Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.58 million for the quarter, compared to the consensus estimate of $3.20 million. On average, analysts expect Tonix Pharmaceuticals to post $-1,763 EPS for the current fiscal year and $-542 EPS for the next fiscal year.

Tonix Pharmaceuticals Stock Down 24.4 %

NASDAQ TNXP opened at $20.17 on Monday. The stock’s 50-day moving average price is $18.79 and its 200-day moving average price is $20.20. The company has a market capitalization of $37.70 million, a P/E ratio of 0.00 and a beta of 2.23. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. Tonix Pharmaceuticals has a 52 week low of $6.76 and a 52 week high of $672.00.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on TNXP shares. StockNews.com started coverage on shares of Tonix Pharmaceuticals in a research report on Monday, February 10th. They issued a “sell” rating for the company. Noble Financial restated an “outperform” rating and set a $70.00 target price on shares of Tonix Pharmaceuticals in a research note on Thursday, March 20th.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.